Annual EBIT
-$78.22 M
-$39.24 M-100.67%
30 June 2024
Summary:
Renovaro Biosciences annual earnings before interest & taxes is currently -$78.22 million, with the most recent change of -$39.24 million (-100.67%) on 30 June 2024. During the last 3 years, it has fallen by -$51.75 million (-195.49%). RENB annual EBIT is now -261489.97% below its all-time high of -$29.90 thousand, reached on 01 March 2012.RENB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$43.96 M
-$29.91 M-212.79%
30 September 2024
Summary:
Renovaro Biosciences quarterly earnings before interest & taxes is currently -$43.96 million, with the most recent change of -$29.91 million (-212.79%) on 30 September 2024. Over the past year, it has dropped by -$39.71 million (-933.40%). RENB quarterly EBIT is now -3855.19% below its all-time high of $1.17 million, reached on 01 June 2019.RENB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$113.17 M
-$34.97 M-44.71%
30 September 2024
Summary:
Renovaro Biosciences TTM earnings before interest & taxes is currently -$113.17 million, with the most recent change of -$34.97 million (-44.71%) on 30 September 2024. Over the past year, it has dropped by -$72.92 million (-181.16%).RENB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RENB EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.7% | -933.4% | -181.2% |
| 3 y3 years | -195.5% | -577.4% | -197.7% |
| 5 y5 years | -334.1% | -2455.2% | -1877.6% |
RENB EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -195.5% | +30.8% | -981.9% | +51.2% | -197.7% | at low |
| 5 y | 5 years | -591.4% | +30.8% | -2825.9% | +51.2% | -2417.7% | at low |
| alltime | all time | <-9999.0% | +30.8% | -3855.2% | +51.2% | <-9999.0% | at low |
Renovaro Biosciences EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$43.96 M(+212.8%) | -$113.17 M(+44.7%) |
| June 2024 | -$78.22 M(+100.7%) | -$14.05 M(-72.4%) | -$78.20 M(-10.2%) |
| Mar 2024 | - | -$50.89 M(+1096.4%) | -$87.08 M(+116.4%) |
| Dec 2023 | - | -$4.25 M(-52.7%) | -$40.25 M(-0.3%) |
| Sept 2023 | - | -$9.00 M(-60.8%) | -$40.36 M(+3.6%) |
| June 2023 | -$38.98 M(-65.5%) | - | - |
| June 2023 | - | -$22.94 M(+464.5%) | -$38.97 M(-63.3%) |
| Mar 2023 | - | -$4.06 M(-6.9%) | -$106.17 M(-1.9%) |
| Dec 2022 | - | -$4.36 M(-42.6%) | -$108.22 M(-1.9%) |
| Sept 2022 | - | -$7.60 M(-91.6%) | -$110.34 M(-2.4%) |
| June 2022 | -$113.06 M(+327.1%) | -$90.14 M(+1376.2%) | -$113.06 M(+181.4%) |
| Mar 2022 | - | -$6.11 M(-5.9%) | -$40.18 M(+5.7%) |
| Dec 2021 | - | -$6.49 M(-37.1%) | -$38.01 M(+10.6%) |
| Sept 2021 | - | -$10.32 M(-40.2%) | -$34.36 M(+29.8%) |
| June 2021 | -$26.47 M(+134.0%) | -$17.27 M(+338.8%) | -$26.47 M(+100.4%) |
| Mar 2021 | - | -$3.94 M(+38.5%) | -$13.21 M(+22.6%) |
| Dec 2020 | - | -$2.84 M(+17.1%) | -$10.78 M(+11.6%) |
| Sept 2020 | - | -$2.43 M(-39.4%) | -$9.66 M(-0.2%) |
| June 2020 | -$11.31 M(-37.2%) | -$4.01 M(+166.6%) | -$9.67 M(+115.2%) |
| Mar 2020 | - | -$1.50 M(-12.7%) | -$4.49 M(-21.5%) |
| Dec 2019 | - | -$1.72 M(-29.6%) | -$5.72 M(-71.5%) |
| Sept 2019 | - | -$2.44 M(-308.6%) | -$20.11 M(+3.2%) |
| June 2019 | -$18.02 M(+186.9%) | $1.17 M(-142.9%) | -$19.48 M(-10.6%) |
| Mar 2019 | - | -$2.73 M(-83.1%) | -$21.78 M(-2.3%) |
| Dec 2018 | - | -$16.11 M(+788.5%) | -$22.29 M(+207.4%) |
| Sept 2018 | - | -$1.81 M(+59.8%) | -$7.25 M(+27.9%) |
| June 2018 | -$6.28 M | -$1.13 M(-65.0%) | -$5.67 M(+20.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$3.24 M(+203.8%) | -$4.71 M(+173.3%) |
| Dec 2017 | - | -$1.07 M(+364.3%) | -$1.72 M(+8.9%) |
| Sept 2017 | - | -$229.60 K(+33.1%) | -$1.58 M(-27.5%) |
| June 2017 | -$2.18 M(-0.7%) | -$172.50 K(-32.1%) | -$2.18 M(-22.9%) |
| Mar 2017 | - | -$254.20 K(-72.5%) | -$2.83 M(+0.5%) |
| Dec 2016 | - | -$925.50 K(+11.6%) | -$2.82 M(+6.2%) |
| Sept 2016 | - | -$829.20 K(+1.1%) | -$2.65 M(+20.7%) |
| June 2016 | -$2.20 M(-19.7%) | -$820.00 K(+240.5%) | -$2.20 M(+59.6%) |
| Mar 2016 | - | -$240.80 K(-68.4%) | -$1.38 M(-42.4%) |
| Dec 2015 | - | -$761.30 K(+103.8%) | -$2.39 M(-8.1%) |
| Sept 2015 | - | -$373.60 K(-70.2%) | -$2.60 M(-21.4%) |
| June 2015 | -$2.73 M(+11.0%) | - | - |
| Mar 2015 | - | -$1.25 M(+29.0%) | -$3.30 M(+34.1%) |
| Dec 2014 | -$2.46 M(+6541.2%) | -$970.70 K(+89.1%) | -$2.46 M(+64.1%) |
| Sept 2014 | - | -$513.40 K(-9.6%) | -$1.50 M(+49.5%) |
| June 2014 | - | -$567.70 K(+37.8%) | -$1.00 M(+128.8%) |
| Mar 2014 | - | -$412.10 K(+4987.7%) | -$438.70 K(+1118.6%) |
| Dec 2013 | - | -$8100.00(-49.4%) | -$36.00 K(-4.0%) |
| Sept 2013 | - | -$16.00 K(+540.0%) | -$37.50 K(+31.6%) |
| June 2013 | - | -$2500.00(-73.4%) | -$28.50 K(-23.0%) |
| Mar 2013 | -$37.10 K(+24.1%) | -$9400.00(-2.1%) | -$37.00 K(+15.6%) |
| Dec 2012 | - | -$9600.00(+37.1%) | -$32.00 K(-5.3%) |
| Sept 2012 | - | -$7000.00(-36.4%) | -$33.80 K(-17.6%) |
| June 2012 | - | -$11.00 K(+150.0%) | -$41.00 K(+36.7%) |
| Mar 2012 | -$29.90 K(-12.8%) | -$4400.00(-61.4%) | -$30.00 K(+17.2%) |
| Dec 2011 | -$34.30 K | -$11.40 K(-19.7%) | -$25.60 K(+80.3%) |
| Sept 2011 | - | -$14.20 K(<-9900.0%) | -$14.20 K(<-9900.0%) |
| June 2011 | - | $0.00 | $0.00 |
FAQ
- What is Renovaro Biosciences annual earnings before interest & taxes?
- What is the all time high annual EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences annual EBIT year-on-year change?
- What is Renovaro Biosciences quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly EBIT year-on-year change?
- What is Renovaro Biosciences TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Renovaro Biosciences?
- What is Renovaro Biosciences TTM EBIT year-on-year change?
What is Renovaro Biosciences annual earnings before interest & taxes?
The current annual EBIT of RENB is -$78.22 M
What is the all time high annual EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high annual earnings before interest & taxes is -$29.90 K
What is Renovaro Biosciences annual EBIT year-on-year change?
Over the past year, RENB annual earnings before interest & taxes has changed by -$39.24 M (-100.67%)
What is Renovaro Biosciences quarterly earnings before interest & taxes?
The current quarterly EBIT of RENB is -$43.96 M
What is the all time high quarterly EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly earnings before interest & taxes is $1.17 M
What is Renovaro Biosciences quarterly EBIT year-on-year change?
Over the past year, RENB quarterly earnings before interest & taxes has changed by -$39.71 M (-933.40%)
What is Renovaro Biosciences TTM earnings before interest & taxes?
The current TTM EBIT of RENB is -$113.17 M
What is the all time high TTM EBIT for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM earnings before interest & taxes is $0.00
What is Renovaro Biosciences TTM EBIT year-on-year change?
Over the past year, RENB TTM earnings before interest & taxes has changed by -$72.92 M (-181.16%)